Halozyme Therapeutics, Inc. (HALO): Halozyme's CEO Presents at BioCentury ... Seeking Alpha If we look across the board whether or not it'd be Roche, product like Herceptin or rituximab, taking these from IV to subcutaneous administration. This is something that we have two products now which have seen European launches in the last quarter ... |
